AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat CystinosisBusiness Wire (press release)CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapi… Continue reading
|
Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
Business Wire (press release) “With immunotherapies dominating the treatment landscape, we continually find that our technology can help our partners, such as Pelican, advance candidates for unmet medical needs including certain cancers,” said Yemi Onakunle, PhD, MBA, Selexis vice … |
|
Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
Business Wire (press release) “With immunotherapies dominating the treatment landscape, we continually find that our technology can help our partners, such as Pelican, advance candidates for unmet medical needs including certain cancers,” said Yemi Onakunle, PhD, MBA, Selexis vice … |
News-Medical.net |
Patented invention has potential to induce and regulate stem cell differentiation
News-Medical.net An invention by Florida Institute of Technology’s Shengyuan Yang was found to naturally narrow the spreading of stem cells and has the potential to induce and regulate their differentiation. Using Yang’s patented and patent-pending technology, stem … |
News-Medical.net |
Patented invention has potential to induce and regulate stem cell differentiation
News-Medical.net An invention by Florida Institute of Technology’s Shengyuan Yang was found to naturally narrow the spreading of stem cells and has the potential to induce and regulate their differentiation. Using Yang’s patented and patent-pending technology, stem … |
|
CCL Sept 2017 – NCI study identifies essential genes for cancer …
The Cancer Letter Publications A new NCI study has identified genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond … |
|
Novartis’s Kymriah becomes first gene therapy to get FDA approval
The Cancer Letter Publications The agent, sponsored by Novartis Pharmaceuticals Corp., was approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia. On July 12, the FDA Oncologic Drugs Advisory Committee unanimously recommended that the agent … |